

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Abortion
 in brucellosis, 467–470
 in Q fever, 472–474
- Adhesion molecules, as bioterrorism agents, 427
- Adjuvants, vaccine, for bioterrorism agents, 511–513
- Adrenal glands, necrosis of, in viral hemorrhagic fevers, 362–363
- Aflatoxins, 394–395
- Agriculture, bioterrorism agents aimed at, 289–290, 395
- Alcian blue stain, for acid mucopolysaccharides, 533
- Alkhurma virus, 350, 359, 476–477
- Amnestic shellfish poisoning, 411–412
- Andes virus, 356–357
- Anemia, in viral hemorrhagic fevers, 348
- Animals, bioterrorism agents related to.
 See Zoonotic bioterrorism agents.
- Anthrax. *See* *Bacillus anthracis*.
- Antibiotics, resistance to, bioterrorism agents and, 291, 293–294
- Antireceptor vaccines, for bioterrorism agents, 508–509
- Antiterrorism Act and Effect Death Penalty Act of 1996, 290–291, 301–302
- Antitoxin, for *Clostridium botulinum* toxin, 403–404
- Arachidonic acid metabolites, as bioterrorism agents, 429–430
- Arenaviridae*, 348–349, 351–354, 372, 476, 528. *See also* *specific viruses*.
- Argentine hemorrhagic fever virus
 diagnosis of, 369
 pathology and pathogenesis of, 362, 364–365, 367–369
 treatment of, 351
 vaccine for, 352
- Aspartate, as bioterrorism agent, 430–431
- Autopsies, in bioterrorism attacks
 Bacillus anthracis, 520–524
 biosafety concerns in, 534–536
 death certificates in, 539
 diagnostic tests for, 519–520
 Francisella tularensis, 525–526
 importance of, 518–519
 Laboratory Response Network resources for, 530, 534
 pitfalls in, 529–530
 poxviruses, 526–528
 procedure for, 520
 public health data derived from, 537–539
 stains for, 530–534
 state authority for, 518
 surveillance role of, 536–537
 variola virus, 526–528
 viral hemorrhagic fever viruses, 528–529
 Yersinia pestis, 524–525

B

- Bacillus anthracis* (anthrax), 318, 460–467
 accidental release of, 288–289, 519
 bioterrorism attack with, 518
 clinical signs of, 464, 520–521
 cutaneous, 520–521
 diagnosis of, 465–467, 523–524
 epidemiology of, 461–463
 etiology of, 461
 gastrointestinal, 521
 inhalational, 334–339, 522–523
 meningitis in, 523
 overview of, 460–461
 pathogenesis of, 463–464
 pathology of, 465, 520–524
 polypeptide capsule of, 463
 public health significance of, 467
 pulmonary, 334–339, 522–523

- Bacillus anthracis* (continued)
 specimen collection in, 523
 stains for, 523–524
 synonyms for, 460
 systemic, 523
 toxins of, 405–406, 463
 transmission of, 461–463
 treatment of, 322–323
 vaccine for, 510, 513
- Bartonella henselae*, 342–344
- Bayou virus, 356–357
- Biolog system, for *Francisella tularensis*, 458
- Biological and Toxin Weapons
 Convention of 1972, 288, 290
- Biological Weapons Antiterrorism Act of 1989, 290
- Bioregulators, as bioterrorism agents, **423–445**
 cytokines, 424–429
 eicosanoids, 429–430
 neurotransmitters, 430–431
 nucleotides, 433–434
 plasma proteases, 432–433
 threat potential of, 434–438
 vasoactive peptides, 431–432
- “Biosafety in Microbiological and Biomedical Laboratories,” 310
- Biosafety levels, for bioterrorism agents, 295–296
Francisella tularensis, 454
 viral hemorrhagic fever viruses, 347
Yersinia pestis, 452
- Biosurety, Select Agent Program as.
See Select Agent Program.
- Bioterrorism agents. *See also specific agents.*
 agricultural use of, 289–290, 395
 bioregulators as, **423–445**
 biosafety levels for, 295–296, 347, 452, 454
 covert attack with, 316
 definition of, 315, 518
 deployment of, 316
 deterrence programs for, 289–291
 emerging, **287–299**
 forensic aspects of, **517–542**
 fungi as, **389–397**
 geographical dissemination of, 316
 government programs for, 288–290
 historical use of, 288–289, 301–302, 315
 immunologic aspects of, **507–515**
 indicators of attack with, 316–317
 mass casualties from, **315–329**
 pediatric considerations in, **331–346**
 radiation resistance and, **493–506**
 recognition of, for prompt action, 289
 Select Agent Program for, **301–314**
 toxins as, **399–421**
 types of, 317–318
 used for publicity, 289–290
 useful characteristics of, 289–290
 variants of, 291, 293
 versus biological agents used legally, 302
 viral hemorrhagic fever viruses. *See* Viral hemorrhagic fever viruses.
 zoonotic, 318, **447–491**, 525–526
- Black Canal Creek virus, 356–357
- Bolivian hemorrhagic fever virus
 diagnosis of, 369
 treatment of, 351
 vaccine for, 352
- Botulism (*Clostridium botulinum*), 318, 400–404
- Bradykinin, as bioterrorism agent, 432–433
- Brain, anthrax manifestations in, 523
- Brazilian hemorrhagic fever virus, treatment of, 351
- Brevetoxin, 412–413
- Brown and Breen tissue Gram stain, for infectious diseases, 531
- Brown-Hopps tissue Gram stain, for infectious diseases, 531
- Brucella*, 467–471
 clinical signs of, 469
 diagnosis of, 470
 epidemiology of, 468–469
 etiology of, 468
 overview of, 467
 pathology of, 469
 public health implications of, 470–471
 vaccine for, 470
- Bubonic plague, 450–451, 524–525
- Buffered *Brucella* antigen tests, 470
- Bunyaviridae*, 348–349, 351–352, 354–357, 373, 477, 528. *See also specific viruses.*
-
- C**
- Card agglutination test, for *Brucella*, 470
- Caribbean ciguatoxin, 410–411

- Cat(s)
Francisella tularensis in, 455–456
Yersinia pestis in, 449–451
- Cat scratch fever (*Bartonella henselae*), 342–344
- Catecholamines, as bioterrorism agents, 430
- Cell culture, in viral hemorrhagic fever virus detection, 371
- Centers for Disease Control (CDC), Select Agent Program of. *See* Select Agent Program.
- Cephalosporium*, mycotoxin from, 392
- Chemical and Biological Weapons Control and Warfare Elimination Act of 1991, 290
- Chemical mediators, in viral hemorrhagic fevers, 363–365
- Chemical Warfare Convention, 290
- Chemokines
 as bioterrorism agents, 426–427, 429
 in viral hemorrhagic fevers, 363–365
 receptors for, agents interfering with, 508
- Cholera (*Vibrio cholerae* toxin), 406–407
- Chronic fatigue syndrome, in Q fever, 473
- Chroococcidiopsis*, radiation resistance in, 495
- Ciguatoxin*, 410–411
- Clostridium baratii* toxin, 400
- Clostridium botulinum* toxin (botulism), 318, 400–404
- Clostridium butyricum* toxin, 400
- Clostridium tetani* toxin (tetanus), 404–405
- Coagulation disorders, in viral hemorrhagic fevers, 365–369
- Coates-Fite stain, for infectious diseases, 532
- Coccidioides*, as bioterrorism agent, 389–392
- Colloidal gold-based
 immunochromatographic assay, for *Clostridium botulinum* toxin, 403
- Colloidal iron stain, for infectious diseases, 533
- Communication, in bioterrorism, 322–323
- Complement fixation test, for *Coxiella burnetii*, 475
- Convention on the Prohibition for the Development and Stockpiling of Bacteriological and Toxin Weapons and on Their Destruction (1972), 288, 290
- Coroners, involvement of, in bioterrorism attacks. *See* Forensic pathology, in bioterrorism attacks.
- Coxiella burnetii* (Q fever), 471–475
 clinical signs of, 472–473
 diagnosis of, 475
 epidemiology of, 472
 etiology of, 471
 overview of, 471
 pathogenesis of, 474–475
 pathology of, 473–474
 public health implications of, 475
 variants of, 475
- Crimean-Congo hemorrhagic fever virus, 349, 355–356, 477
 diagnosis of, 369
 pathology and pathogenesis of, 367–368
 vaccine for, 510
- Culture
Bacillus anthracis, 466
Brucella, 468
Francisella tularensis, 458
Yersinia pestis, 452
- Cutaneous anthrax, 463–464, 520–521
- Cytokines
 as bioterrorism agents, 424–429
 in viral hemorrhagic fevers, 363–365
- Cytology, for *Bacillus anthracis*, 465–466
- Cytosine-guanosine oligodeoxynucleotides, as vaccine adjuvants, 511–512
-
- D**
- Death, in bioterrorism. *See also* Autopsies, in bioterrorism attacks.
 mortuary affairs for, 327, 537–539
- Decontamination, in bioterrorism attack, 324–325, 535–536
- Deinococcus radiodurans*, reactive oxygen species resistance in, **493–506**
 classical view of, 494–495
 genetic basis of, 495–497
 manganese in, 495, 497–503
 mitochondria and, 500–502
 protein targets in, 498–500

- Deinococcus radiodurans* (continued)
radiation resistance modulators based on, 502–503
- Dengue virus, 350, 358–359, 371, 476–477
- Deoxyribose, 392
- Department of Agriculture, Select Agent Program of. *See* Select Agent Program.
- Department of Defense, Select Agent Program and. *See* Select Agent Program.
- Dieterle silver impregnation procedure, for infectious diseases, 532
- Dinoflagellates, ciguatoxin from, 410–415
- Direct fluorescent antibody test
for *Francisella tularensis*, 458, 526
for *Yersinia pestis*, 453
- Disaster Mortuary Operational Response Teams, in bioterrorism, 327, 537–538
- Disseminated intravascular coagulation, in viral hemorrhagic fevers, 366–368
- DNA
as bioterrorism agent, 433–434
radiation damage of, 494–497
subunits of, vaccines made from, for bioterrorism agents, 509–511
- DNA analysis, for *Yersinia pestis*, 453
- DNA microarray analysis, for *Francisella tularensis*, 459
- Dobrava virus, 356–357
- Dogs
Francisella tularensis in, 455–456
Yersinia pestis exposure of, 450
- Domoic acid, 411–412
- Dopamine, as bioterrorism agent, 430

E

- Ebola virus, 350, 476
bioterrorism potential of, 359–360
diagnosis of, 369, 371
outbreaks of, 357–358
pathology and pathogenesis of, 360–368, 528
structure of, 373
vaccine for, 353, 508–510
- Edema
in anthrax
central nervous system, 523
gastrointestinal, 521

- inhalational, 522–523
pulmonary, in smallpox, 526–527
- Edema factor, *Bacillus anthracis*, 405–406, 463
- Eicosanoids, as bioterrorism agents, 429–430
- Electron microscopy
for variola virus, 527–528
for viral hemorrhagic fever viruses, 371–372, 529
- Emergency management plan
for mass casualties, 320–327
in Select Agent Program, 309
- Encephalitis, in Rift Valley fever, 480–481
- Endocarditis, in Q fever, 473
- Endothelial damage, in viral hemorrhagic fevers, 361–362
- Endothelins, as bioterrorism agents, 430–431
- Endotoxins, bacterial, 400
- Enterocolitis, hemorrhagic, 407–408
- Enterotoxins, bacterial, 400, 409–410
- Enzyme-linked immunosorbent assays
for *Brucella*, 470
for *Clostridium botulinum* toxin, 403
for *Coxiella burnetii*, 475
for cytokines, 426
for domoic acid, 412
for Rift Valley fever virus, 481
for Shigatoxin-producing bacteria, 408
for viral hemorrhagic fever viruses, 371
for *Yersinia pestis*, 453
- Epinephrine, as bioterrorism agent, 430
- Ergot alkaloids, 394
- Escherichia coli*, Shigatoxins of, 407–408
- Exotoxins, bacterial, 400

F

- Federal Bureau of Investigation, action of, in bioterrorism, 322, 538–539
- Fetus, *Coxiella burnetii* effects on, 474
- Fibrinolysis, in viral hemorrhagic fevers, 367–368
- Filoviridae*, 348, 350, 352, 357–358, 373, 476, 528. *See also specific viruses.*
- Fish, toxins in, 413–414

Fite-Faraco method, for acid-fast bacteria, 531–532

Flat-type smallpox, 527

Flaviviridae, 348, 350, 352, 358–359, 373–374, 476–477, 528.
See also *specific viruses*.

Fleas, in *Yersinia pestis* transmission, 448–449

Fluorescence polarization assay, for *Brucella*, 470

Fontana-Masson stain, for infectious diseases, 533–534

Forensic pathology, in bioterrorism attacks, **517–542**
Bacillus anthracis, 520–524
biosafety concerns in, 534–536
data collection, analysis and dissemination in, 537–539
diagnostic tests, 519–520
Francisella tularensis, 525–526
involvement of, 517–518
Laboratory Response Network in, 530, 534
pitfalls in, 529–530
poxviridae, 526–528
stains for, 530–534
surveillance role of, 536–537
variola virus, 526–528
viral hemorrhagic fever viruses, 528–529
Yersinia pestis, 524–525

Fraction-1 antigen, *Yersinia pestis*, 448

Francisella tularensis (tularemia), 318, 453–460
aquatic cycle of, 454–455
clinical signs of, 456–457
diagnosis of, 458–459
epidemiology of, 454–456
etiology of, 454
oculoglandular, 457, 525
oropharyngeal, 457, 525
overview of, 453–454
pathogenesis of, 456
pathology of, 457–458, 525–526
pneumonic, 457, 460, 525
public health implications of, 459–460
subspecies of, 454
terrestrial cycle of, 454–455
typhoidal, 525
ulceroglandular, 456–457, 525

Fumonisin, 394

Fungi, as bioterrorism agents, **389–397**
Coccidioides, 389–392
crop diseases as, 395

mycotoxins in, 392–395

Fusarium, mycotoxin from, 392

G

Gambierdiscus toxicus, ciguatoxin from, 410–411

Gamma-aminobutyric acid, as bioterrorism agent, 430–431

Ganglioside–liposome bioassay, for *Clostridium botulinum* toxin, 403

Gangrene, in plague, 524

Gastrointestinal anthrax, 521

Gene transfer, for bioterrorism, 433–434, 437

Giemsa stain
for *Coxiella burnetii*, 471
for infectious diseases, 531

Gimenez stain, for *Coxiella burnetii*, 471

Glandular tularemia, 457

Glutamate, as bioterrorism agent, 430–431

Glycine, as bioterrorism agent, 430–431

Gonyautoxins, 414–415

Gram stain, for infectious diseases, 531

Granulomas, in tularemia, 457–458

Gridley fungus stain, 533

Grocott's methenamine silver stain, for infectious diseases, 532–533

Growth factors, as bioterrorism agents, 426

Guanarito virus, 349, 353–354, 476

Guarnieri bodies, in smallpox, 526, 528

H

Hantaan virus, 356–357, 477, 510

Hantavirus(es), 349, 356–357, 477
bioterrorism potential of, 359
diagnosis of, 369, 371
laboratory tests in, 348
pathology and pathogenesis of, 361–362, 364
structure of, 373
treatment of, 351

Hantavirus pulmonary syndrome, 357

Heat shock proteins, as vaccine adjuvants, 512

Hematoxylin and eosin stain, for infectious diseases, 531

Hemoconcentration, in viral hemorrhagic fevers, 348

Hemolytic uremic syndrome, 407–408

Hemorrhage
in anthrax
 central nervous system, 523
 cutaneous, 520–521
 gastrointestinal, 521
 inhalational, 522–523
in smallpox, 527
in viral hemorrhagic fevers, 528

Hemorrhagic enterocolitis, 407–408

Hemorrhagic fever viruses, viral. *See* Viral hemorrhagic fever viruses; *specific viruses*.

Human immunodeficiency virus infection, vaccines for
 antireceptor, 508
 DNA plasmid, 509

I

Immune response
 innate, activation of, against bioterrorism agents, 513–514
 suppression of, in viral hemorrhagic fevers, 363

Immunobead assay, for ciguatoxin, 411

Immunochromatographic membrane-based assay, for *Francisella tularensis*, 459

Immunofluorescence tests, for Rift Valley fever virus, 481

Immunohistochemistry
 for *Francisella tularensis*, 458, 526
 for variola virus, 538
 for viral hemorrhagic fever viruses, 371–372, 529
 for *Yersinia pestis*, 453, 525

Indirect immunofluorescence assays, for *Coxiella burnetii*, 475

Infant botulism, 401

Inhalational anthrax, 463–464, 522–523

Interferons
 as bioterrorism agents, 426–429
 for viral hemorrhagic fevers treatment, 352
 in viral hemorrhagic fever pathogenesis, 363–365

Interleukins
 as bioterrorism agents, 426–429
 in viral hemorrhagic fevers, 363–365

Ionizing radiation resistance, in bacteria. *See* *Deinococcus radiodurans*.

Iron, in radiation resistance, 498–499

J

Junin virus, 349, 354, 359–360, 476

K

Kallikreins, as bioterrorism agents, 432–433

Karenia brevis, brevetoxin from, 412–413

Korean hemorrhagic fever with renal syndrome, 356–357, 368

Kyasanur Forest virus, 350, 359, 476–477

L

Laboratory Response Network
 medical examiner resources in, 530, 534
 Select Agent Program and, 305

Lactobacillus plantarum, radiation resistance in, 497

Lassa fever virus, 349, 353–354, 476
 bioterrorism potential of, 359–360
 laboratory tests for, 348
 pathology and pathogenesis of, 361–362, 365, 368
 treatment of, 351

Legislation, on bioterrorism agents, 290–291, 301–303, 323

Lethal factor, *Bacillus anthracis*, 405–406, 463

Leukopenia, in viral hemorrhagic fevers, 348

Leukotrienes, as bioterrorism agents, 429–430

Liquid chromatography, in paralytic shellfish poisoning, 415

Liver, pathology of
 in anthrax, 523
 in Rift Valley fever, 480–481
 in viral hemorrhagic fevers, 362

Lymphadenopathy
 in anthrax, 465
 cutaneous, 520–521
 inhalational, 522–523

- in monkeypox, 527
 - in plague, 451–452, 524–525
 - in tularemia, 457–458, 525–526
 - in viral hemorrhagic fevers, 528
- Lymphocytes, depletion of, in viral hemorrhagic fevers, 363
- M**

- Machupo virus, 349, 353–354, 476
 - bioterrorism potential of, 359
 - pathology and pathogenesis of, 362, 368
- McManus periodic acid-Schiff stain, for infectious diseases, 533
- Manganese, in radiation resistance, 495, 497–503
- Marburg virus, 350, 476
 - bioterrorism potential of, 359–360
 - diagnosis of, 369, 371
 - outbreaks of, 357–358
 - pathology and pathogenesis of, 361–363, 366–367, 528
 - structure of, 373
 - vaccine for, 508–510
- Marine toxins, 410–415
- Mass casualties, from bioterrorism agents, **315–329**
 - decontamination in, 324–325
 - definition of, 319
 - epidemiologic investigation in, 321–322
 - health care facilities for, 324
 - health care workers available for, 326–327
 - health risk communication in, 322–323
 - incident management system for, 319–320
 - legal aspects of, 323
 - mortuary affairs for, 327
 - multidisciplinary coordination in, 322
 - personal protective equipment for, 325
 - prophylaxis for, 326
 - psychologic aspects of, 326
 - quarantine in, 323
 - special population risks in, 327–328
 - stockpiling supplies for, 325–326
 - surge capacity in, 320–321
 - triage in, 324
- Masson's trichrome stain, for infectious diseases, 533
- Mayer's mucicarmine stain, for infectious diseases, 533
- Medical examiners, involvement of, in bioterrorism attacks. *See* Forensic pathology, in bioterrorism attacks.
- Meningitis
 - Bacillus anthracis*, 523
 - Yersinia pestis*, 525
- Methenamine silver stain, for infectious diseases, 532–533
- Metronidazole, for tetanus, 405
- Microagglutination test, for *Francisella tularensis*, 459
- Micrococcus luteus*, radiation sensitivity of, 495
- Microspheres, as vaccine adjuvants, 512–513
- Milk ring test, for *Brucella*, 470
- Mitochondria, radiation toxicity to, 500–502
- Monkeypox, pathology of, 527
- Mortuary affairs, in bioterrorism attacks, 327, 537–539
- Mouse bioassay
 - for ciguatoxin, 411
 - for *Clostridium botulinum* toxin, 403
 - for domoic acid, 412
- Movat pentachrome method, for infectious diseases, 533
- mRNA, in cytokines, 425–426
- Mucicarmine stain, for infectious diseases, 533
- Muscle spasms, in tetanus, 404
- Mycotoxins, 392–395
- Myrothecium*, mycotoxin from, 392
- N**

- Nairoviruses, 373, 477
- Necrosis
 - in anthrax, 521
 - in plague, 451, 524–525
 - in tularemia, 457–458, 525
 - in viral hemorrhagic fevers, 528
- Neonates, tetanus in, 404
- Neosaxitoxin, 414–415
- Neurokinins, as bioterrorism agents, 430–432

Neuropeptides, as bioterrorism agents, 430–432

Neurotensins, as bioterrorism agents, 430–431

Neurotransmitters, as bioterrorism agents, 430–431

New York virus, 356–357

Nitric oxide, in viral hemorrhagic fevers, 364–365

Norepinephrine, as bioterrorism agent, 430

Nuclear factor- κ B, as bioterrorism agent, 427

Nucleotides, as bioterrorism agents, 433–434

O

Oculoglandular tularemia, 457

Omsk hemorrhagic fever virus, 350, 359, 476–477

Opioids, as bioterrorism agents, 430

Oropharyngeal anthrax, 462

Oropharyngeal tularemia, 457, 525

Overlap agents and toxins, in Select Agent Program, 304, 306–307

Oxygen reactive species
in bacterial radiation resistance.
See Deinococcus radiodurans.
in viral hemorrhagic fevers, 364–365

P

Pacific ciguatoxin, 410–411

Paralytic shellfish poisoning, 414–415

Pathogenicity islands, bioterrorism agents and, 294

Patriot Act, 302

Pediatric patients, bioterrorism agents affecting, **331–346**
Bacillus anthracis, 334–339
variola virus, 331–333
versus *Bartonella henselae*, 342–344
versus respiratory syncytial virus, 336–339
versus varicella-zoster virus, 332–333
Yersinia pestis, 339–344

Pentachrome method, for infectious diseases, 533

Periodic acid-Schiff stain, for infectious diseases, 533

Peritonitis, in anthrax, 523

Peronosclerospora philippinensis, 395

Personal protective equipment, for bioterrorism agents, 325

Phakospora pachyrhizi, 395

Pharyngeal plague, 451

Pharyngogastrointestinal anthrax, 464–465

Philippine hemorrhagic fever, 359

Phytophthora infestans, 395

Placenta, pathology of
in brucellosis, 469
in Q fever, 473–475

Plague. *See Yersinia pestis* (plague).

Plasma proteases, as bioterrorism agents, 432–433

Plasmids, vaccines made from, for bioterrorism agents, 509–511

Plate agglutination test, for *Brucella*, 470

Pleural effusion, in anthrax, 523

Pneumonic plague, 450–451, 453

Pneumonic tularemia, 457, 460, 525

Polymerase chain reaction
for *Bacillus anthracis*, 466
for *Coxiella burnetii*, 475
for *Francisella tularensis*, 458–459
for Rift Valley fever virus, 481
for viral hemorrhagic fever viruses, 371
for *Yersinia pestis*, 453

Poxviruses, 526–528. *See also* Variola virus (smallpox).

Prostanoids, as bioterrorism agents, 429–430

Proteases, as bioterrorism agents, 432–433

Protective antigen, *Bacillus anthracis*, 405–406, 463

Proteins, radiation damage of, 498–500

Pseudomonas putida, radiation sensitivity of, 495

Pseudo-nitzschia multiseriata, domoic acid from, 411–412

Psychologic aspects, of bioterrorism, 326

Public Health Security and Bioterrorism Preparedness and Response Act of 2002, 303

Puffer fish toxins, 413–414

Pulmonary edema, in smallpox, 526–527

Putrefaction, in anthrax, 465

Puumala virus, 356–357

Q

Q fever (*Coxiella burnetii*), 471–475

Quarantine, in bioterrorism attack, 323

R

Rabbits, *Francisella tularensis* in, 454–455

Radiation resistance, in bacteria.
See Deinococcus radiodurans.

Rash, in viral hemorrhagic fevers, 366

Reactive oxygen and nitrogen species
in bacterial radiation resistance.
See Deinococcus radiodurans.
in viral hemorrhagic fevers, 364–365

Regulations, on bioterrorism agents, Select Agent Program as. *See* Select Agent Program.

Resistance, antibiotic, bioterrorism agents and, 291, 293–294

Respiratory syncytial virus, versus pulmonary anthrax, 336–339

Responsible official, for Select Agent Program, 305, 308–309

Retinitis, in Rift Valley fever, 480–481

Ribavirin, for viral hemorrhagic fevers, 351–352

Ricin, 318

Rift Valley fever virus, 349, 354–355, 476–482
bioterrorism potential of, 360
clinical manifestations of, 479–480
diagnosis of, 369, 481
epidemiology of, 478–479
etiology of, 478
laboratory tests for, 348
overview of, 476–478
pathology and pathogenesis of, 365, 368
pathophysiology of, 480–481
public health implications of, 482
treatment of, 351
vaccine for, 352, 510

RNA, as bioterrorism agent, 433–434

Rodents, *Yersinia pestis* in, 448–449

S

Sabia virus, 349, 353–354, 476

Safeguarding Biological Select Agents and Toxins, 303–304, 310–312

Safety. *See also* Biosafety levels.
in bioterrorism attacks, in autopsies, 534–536
in Select Agent Program, 310

Saxitoxins, 414–415

Scarring, in smallpox, 526

Sclerophthora rayssiae, 395

Security, in Select Agent Program, 310

Select Agent Program, **301–314**
agents in
 accountability for, 311–312
 categories of, 304
 list of, 306–307
clinical laboratory involvement in, 304–308
 agent accountability in, 311–312
 management in, 308–310
 personnel reliability and, 312
 registration for, 304–305, 308
 safety in, 310
 security in, 310–311
 training for, 308
origins of, 301–304

Seoul virus, 356–357, 477

Septicemia, in anthrax, 462–465

Septicemic plague, 450, 524–525

Serologic testing
 for *Brucella*, 470
 for *Coxiella burnetii*, 475
 for *Francisella tularensis*, 459

Serotonin, as bioterrorism agent, 430

Shellfish poisoning
 amnestic, 411–412
 paralytic, 414–415

Shewanella oneidensis, radiation sensitivity of, 495

Shigatoxins, 407–408

Shigella dysenteriae, Shigatoxins of, 407–408

Simian immunodeficiency virus, vaccine for, 512

Sin Nombre virus, 356–357, 371, 477

Skin

- anthrax manifestations in, 463–464, 520–521
- smallpox manifestations in, 526–527

Smallpox. *See* Variola virus.

Sodium-channel assay, for paralytic shellfish poisoning, 415

Spleen, anthrax manifestations in, 523

Splenomegaly, in anthrax, 465

Spores, *Bacillus anthracis*, 461–462, 467

Stachybotrys, mycotoxin from, 392–393

Stains, for bioterrorism agents, 530–534
Coxiella burnetii, 471
Yersinia pestis, 452

Staphylococcus aureus, enterotoxin B of, 409–410

Steiner stain, for infectious diseases, 532

Streptococci, group B, DNA subunit vaccine for, 509

Subarachnoid hemorrhage, in anthrax, 523

Substance P, as bioterrorism agent, 431–432

Superantigen, *Staphylococcus aureus*, 409–410

Superoxide scavengers, for radiation resistance modulation, 502–503

Surety, for biological agents, Select Agent Program as. *See* Select Agent Program.

Surveillance, in bioterrorism, autopsy role in, 536–537

Synchytrium endobioticum, 395

T

Tachykinins, as bioterrorism agents, 430

Terrorism, biological agents in. *See* Bioterrorism agents.

Tetanospasmin, 404–405

Tetanus (*Clostridium tetani* toxin), 404–405

Tetrodotoxin, 413–414

Thomas stain, for infectious diseases, 532

Thrombocytopenia, in viral hemorrhagic fevers, 348, 366, 369

Tissue factor, as bioterrorism agent, 433

Tourniquet test, in viral hemorrhagic fevers, 369

Toxins, 399–421

- bacterial, 400–410
- classification of, 399–400
- definition of, 399
- in Select Agent Program. *See* Select Agent Program.
- marine, 410–415
- therapeutic use of, 415

Transforming growth factor- β , as bioterrorism agent, 428

Triage, in bioterrorism attack, 324

Trichoderma, mycotoxin from, 392

Trichothecenes, 392–394

Tube agglutination test, for *Brucella*, 470

Tularemia. *See* *Francisella tularensis* (tularemia).

Tumor necrosis factor- α , as bioterrorism agent, 426–428

Typhoidal tularemia, 525

U

Ulceroglandular tularemia, 456–457, 525

Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism (Patriot Act), 302

Ustilago tritici, 395

V

Vaccination, for bioterrorism agents, 326,

507–515

- adjuvants for, 511–513
- alternatives to
 - antireceptor vaccines, 508–509
 - DNA subunit/plasmid vaccines, 509–511
 - innate immunity augmentation, 513–514

Bacillus anthracis, 510, 513

Brucella, 470

human immunodeficiency virus, 508–509

simian immunodeficiency virus, 512

streptococci group B, 509

variola virus, 508

viral hemorrhagic fever viruses, 352–353

- Vaccinia virus, pathology of, 526–528
- Varicella-zoster virus, versus variola virus, 332–333
- Variola minor, pathology of, 526–528
- Variola virus (smallpox), 318
 clinical signs of, 526–527
 diagnosis of, 528
 in pediatric patients, 331–333
 pathology of, 526–528
 personal protective equipment for, 325
 specimens from, 527–528
 types of, 526
 vaccines for, 508
- Vasoactive peptides, as bioterrorism agents, 431–432
- Venezuelan equine encephalitis virus, 510
- Verotoxin, 407–408
- Verticomonosporium*, mycotoxin from, 392
- Vibrio cholerae* toxin (cholera), 406–407
- Viral hemorrhagic fever viruses, 318
Arenaviridae, 348–349, 351–354, 372, 476, 528
 biosafety levels of, 347
Bunyaviridae, 348–349, 351–352, 354–357, 373, 477, 528
 characteristics of, 347, 372–374
 diagnosis of, 369–372
 differential diagnosis of, 370–371
 epidemiology of, 348
Filoviridae, 348, 350, 352, 357–358, 373, 476, 528
Flaviviridae, 348, 350, 352, 358–359, 373–374, 476–477, 528
 geographical distribution of, 349–350
 incubation period for, 348–350
 laboratory tests in, 348, 351, 369–372
 mortality in, 348–350
 overview of, 476–478
 pathology and pathogenesis of, 360–369
 reservoirs for, 349–350
 symptoms of, 348, 369
 transmission of, 349–350
 treatment of, 351–352
 types of, 476–477
 vaccines for, 352–353, 510
- Vomitoxin, 392

W

- Warfare, biological. *See* Bioterrorism agents.

- Warthin-Starry stain, for infectious diseases, 532
- Weapons, biological. *See* Bioterrorism agents.
- Wenger-Angritt procedure, for argyrophilic bacteria, 532
- Whitewater Arroyo virus, 349, 353–354, 476
- Whitewater virus, 349
- Wound botulism, 402

Y

- Yellow fever virus, 350, 358–359, 476
 bioterrorism potential of, 360
 pathology and pathogenesis of, 362, 368
 vaccine for, 352
- Yersinia pestis* (plague), 318, 447–453
 biosafety levels for, 452
 bubonic, 450–451, 524–525
 clinical signs of, 450–451
 diagnosis of, 452–453
 epidemiology of, 448–449
 etiology of, 448
 in pediatric patients, 339–344
 laboratory tests in, 344
 overview of, 447–448
 pathogenesis of, 449–450
 pathology of, 451–452, 524–525
 pneumonic, 524–525
 public health implications of, 453
 septicemic, 450, 524–525
 transmission of, 343
 types of, 524
- Yersinia pseudotuberculosis*, 448

Z

- Ziehl-Neelsen acid-fast stain, for infectious diseases, 531
- Zoonotic bioterrorism agents, **447–491**
Bacillus anthracis. *See* *Bacillus anthracis*.
Brucella, 467–471
Coxiella burnetii, 471–475
Francisella tularensis, 318, 453–460, 525–526
 viral hemorrhagic fever viruses.
See Viral hemorrhagic fever viruses; *specific viruses*.
Yersinia pestis. *See* *Yersinia pestis* (plague).